Promoting ENW on CZO's boardPlease stop it. ENW has nothing to do with dirt-cheap, debt-free, profitable Ceapro (CZO) that trades
just 8 times its 2020 EBITDA while being a takeover target by a larger healthcare company or a foods company. Specifically, CZO is working on two game changers that are strong catalysts and could push CZO much higher than its current price such as:
CZO's PGX oat beta glucan: Quaker Oats advertises that its oatmeal lowers cholesterol. This is a fact. You can see it in the company's TV commercials and on Youtube. Meanwhile, CZO's oat beta glucan is in a human clinical trial under the influencial Dr. Jean Claude Tardif at the Montreal Heart Institute. Patients are being enrolled and randomized and results are expected very soon. CZO is using its Oat Beta Glucan for the cholesterol reducing pill and a functional drink, facts below:
https://www.ceapro.com/nutraceuticals/oat-beta-glucan
CZO's PGX yeast beta glucan: The Canadian Government has provided funding towards mass production and a clinical trial. CZO collaborates with McMaster, a university that ranks in the top 1% of universities in the world.This PGX-YBG will be tested as a potential inhalable therapeutic for COVID-19 and other fibrotic end-point diseases of the lung, facts below:
https://www.globenewswire.com/news-release/2020/11/27/2135353/0/en/Ceapro-Inc-Reports-2020-Third-Quarter-and-Nine-Month-Financial-Results-and-Operational-Highlights.html